Analyst Price Targets — KROS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2024 6:47 pm | Kelly Shi | Jefferies | $107.00 | $62.02 | StreetInsider | Jefferies Starts Keros Therapeutics (KROS) at Buy |
| November 5, 2024 11:06 am | Srikripa Devarakonda | Truist Financial | $100.00 | $62.02 | StreetInsider | Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS) |
| September 23, 2024 2:57 am | Vamil Divan | Guggenheim | $96.00 | $55.80 | StreetInsider | Guggenheim Starts Keros Therapeutics (KROS) at Buy |
| June 18, 2024 7:57 am | Joseph Catanzaro | Piper Sandler | $105.00 | $44.65 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS) |
| December 13, 2022 8:49 am | — | BTIG | $105.00 | $49.98 | Benzinga | BTIG Maintains Buy on Keros Therapeutics, Raises Price Target to $105 |
| July 27, 2022 7:59 pm | Julian Harrison | BTIG | $80.00 | $31.79 | Pulse 2.0 | Keros Therapeutics (KROS) Stock: Why It Surged 11.43% Today |
| May 18, 2022 10:06 am | Joseph Catanzaro | Piper Sandler | $120.00 | $39.92 | TheFly | Keros Therapeutics price target raised to $120 from $90 at Piper Sandler |
Latest News for KROS
JPMorgan Chase and Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ: KROS) by 260.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,941 shares of the company's stock after buying an additional 124,287 shares during the
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KROS.
U.S. House Trading
No House trades found for KROS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.